Vaxcyte Completes Enrollment Of Phase 2 Study Evaluating VAX-24 For Prevention Of Invasive Pneumococcal Disease In Infants

3/4/24 8:34:06 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PCVX alert in real time by email

-- Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by the End of the First Quarter of 2025, Followed by Topline Data from Booster Dose by the End of 2025 --

-- VAX-24, a 24-Valent Pneumococcal Conjugate Vaccine (PCV), is Designed to Cover More Serotypes Than Any Infant Pneumococcal Vaccine On-Market or in U.S. Clinics Today --

-- Company's Potential Best-in-Class, Carrier-Sparing PCV Programs, VAX-24 and VAX-31, Intended to Deliver the Broadest-Spectrum of Coverage Against IPD --

Get the next $PCVX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PCVX

Date	Price Target	Rating	Analyst
12/7/2023	$69.00	Buy	Mizuho
4/18/2023		Outperform	TD Cowen
1/3/2023	$52.00 → $58.00	Buy	Needham
12/15/2022	$66.00	Buy	Guggenheim
11/17/2022	$69.00	Buy	BTIG Research
12/29/2021	$50.00	Buy	Jefferies
6/24/2021	$50.00	Buy	Jefferies

More analyst ratings

$PCVX
Press Releases

Fastest customizable press release news feed in the world

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
-- VAX-31 Infant Indication: Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of January 2025 -- -- VAX-31 Adult Indication: Breakthrough Therapy Designation Granted by FDA; Company Plans to Initiate Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 -- -- VAX-31, Designed to Cover Currently Circulating and Historically Prevalent Strains, is Being Studied for the Prevention of Invasive Pneumococcal Disease in the Pediatric and Adult Populations -- SAN CARLOS, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines
11/12/24 7:30:11 AM ET
$PCVX
Biotechnology: Pharmaceutical Preparations
Health Care
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, in Adults Aged 50 and Older -- -- PCV Adult Indication: VAX-31 Selected to Advance to Phase 3 Program; Initiation of Phase 3 Pivotal, Non-Inferiority Study Expected by Mid-2025 and Announcement of Topline Safety, Tolerability and Immunogenicity Data in 2026 -- -- PCV Pediatric Indication: VAX-24 Infant Phase 2 Study Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025; Initiation of VAX-31 Infant Phase 2 Study Expected in First Quarter of 2025 Subject to IND Application Clearance by
11/5/24 4:01:35 PM ET
$PCVX
Biotechnology: Pharmaceutical Preparations
Health Care
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company's website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference. About VaxcyteVaxcyte is a vaccine innova
9/11/24 4:05:03 PM ET
$PCVX
Biotechnology: Pharmaceutical Preparations
Health Care

$PCVX
Leadership Updates

Live Leadership Updates

Vaxcyte Appoints John Furey to Board of Directors
SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed John Furey, a seasoned industry expert, to its Board of Directors. "We are thrilled to welcome John to Vaxcyte's Board of Directors and look forward to benefiting from his wealth of biopharmaceutical and vaccine expertise, including the manufacture, supply and commercialization of pneumococcal conjugate vaccines (PCVs)," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "As we continue to progress our PCV candidates, VAX-24
7/2/24 8:30:00 AM ET
$PCVX
Biotechnology: Pharmaceutical Preparations
Health Care
Vaxcyte Appoints Whitney Jones as Chief People Officer
-- Ms. Jones Joins Vaxcyte With Over 20 Years of Experience Leading People and Culture Strategies Across Multiple Industries -- SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Whitney Jones as Chief People Officer. Ms. Jones will lead Vaxcyte's human resources strategy and operations, including people and culture, talent acquisition and management, learning and development, total rewards and employee engagement. "At Vaxcyte, we are proud to cultivate a culture that values coll
1/16/24 4:01:00 PM ET
$PCVX
Biotechnology: Pharmaceutical Preparations
Health Care
Vaxcyte Appoints Jacks Lee to Board of Directors
SAN CARLOS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Jacks Lee to its Board of Directors. "We are pleased to welcome Jacks, an accomplished industry leader with extensive biopharmaceutical and vaccine manufacturing, supply and operations expertise, to Vaxcyte's Board of Directors as we continue to realize our mission of developing vaccines to address serious bacterial illnesses," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "Jacks will provide strategic insights across
11/28/23 8:30:00 AM ET
$PCVX
Biotechnology: Pharmaceutical Preparations
Health Care

$PCVX
Financials

Live finance-specific insights

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
-- At All Doses Studied, VAX-31 Demonstrated Robust Opsonophagocytic Activity Immune Responses for All 31 Serotypes -- -- At Middle and High Doses, VAX-31 Met or Exceeded Regulatory Immunogenicity Criteria for All 31 Serotypes -- -- At All Doses Studied, VAX-31 Was Observed to be Well Tolerated and Demonstrated a Safety Profile Similar to Prevnar 20® -- -- Topline Results Further Validate Potential of Vaxcyte's Carrier-Sparing Platform to Deliver Broadest-Spectrum Pneumococcal Conjugate Vaccine Candidates that Provide Protection Against Both Currently Circulating and Historically Prevalent Serotypes -- -- For Adult Indication, VAX-31 Selected to Advance to Phase 3 Program; Vaxcyte Plans
9/3/24 7:07:43 AM ET
$PCVX
Biotechnology: Pharmaceutical Preparations
Health Care
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older
SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, September 3, 2024, at 8:00 a.m. Eastern Time to present topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the Company's 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy adults aged 50 and older. To participate in the conference call, please dial 800-225-9448 (domest
9/2/24 6:40:59 PM ET
$PCVX
Biotechnology: Pharmaceutical Preparations
Health Care
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
SAN CARLOS, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2023 after market close on February 27, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update. To participate in the conference call, please dial (800) 225-9448 (domestic) or (203) 518-9708 (international) and refer to conference ID PCVXQ423. A live we
2/15/24 4:05:00 PM ET
$PCVX
Biotechnology: Pharmaceutical Preparations
Health Care

Vaxcyte Completes Enrollment Of Phase 2 Study Evaluating VAX-24 For Prevention Of Invasive Pneumococcal Disease In Infants

Chat with this insight

Recent Analyst Ratings for $PCVX

$PCVX Press Releases

Fastest customizable press release news feed in the world

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

$PCVX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

PRESIDENT AND CFO Guggenhime Andrew exercised 8,000 shares at a strike of $5.35 and sold $686,518 worth of shares (8,000 units at $85.81) (SEC Form 4)

CHIEF EXECUTIVE OFFICER Pickering Grant gifted 710 shares, decreasing direct ownership by 0.15% to 465,301 units (SEC Form 4)

SEC Form 4 filed by SVP, FINANCE Cowan Elvia

$PCVX Leadership Updates

Live Leadership Updates

Vaxcyte Appoints John Furey to Board of Directors

Vaxcyte Appoints Whitney Jones as Chief People Officer

Vaxcyte Appoints Jacks Lee to Board of Directors

$PCVX SEC Filings

Vaxcyte Inc. filed SEC Form 8-K: Other Events

SEC Form 144 filed by Vaxcyte Inc.

SEC Form 144 filed by Vaxcyte Inc.

$PCVX Market Insights

Live Market Insights

Needham Reiterates Buy on Vaxcyte, Maintains $95 Price Target

Cantor Fitzgerald Reiterates Overweight on Vaxcyte

Cantor Fitzgerald Reiterates Overweight on Vaxcyte

$PCVX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

$PCVX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Mizuho initiated coverage on Vaxcyte with a new price target

TD Cowen initiated coverage on Vaxcyte

Needham reiterated coverage on Vaxcyte with a new price target

$PCVX Financials

Live finance-specific insights

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Recent Analyst Ratings for
$PCVX

$PCVX
Press Releases

$PCVX
Insider Trading

$PCVX
Leadership Updates

$PCVX
SEC Filings

$PCVX
Market Insights

$PCVX
Large Ownership Changes

$PCVX
Analyst Ratings

$PCVX
Financials